Bone marrow transplantation (BMT) for acute lymphoblastic leukemia (ALL) in remission

M. T. van Lint, A. Bacigalupo, F. Frassoni, M. Repetto, G. Piaggio, M. Congiu, V. Vitale, D. Scarpati, P. Franzone, R. Corvò

Research output: Contribution to journalArticlepeer-review


Thirty-two patients with acute lymphoblastic leukemia (ALL) were given cyclophosphamide, 120 mg/kg, and total body irradiation (TBI), 10-12 Gy, followed by an allergic bone marrow transplant (BMT). Seven patients were in their first remission: 4 survived 8-24 months post-BMT and 3 died of BMT-related complications. Twenty-five patients were in their second remission: 12 survived, 7-50 months post-BMT. The actuarial survival for patients in 1st and 2nd CR is 57% and 40 %, respectively (p = 0.1). The overall survival for patients less than or older than 15 years of age is 73% and 50%, respectively (p = 0.2). The actuarial risk of relapse is currently 0% and 50% for 1st and 2nd CR patients (p = 0.06). Factors influencing relapse in 2nd CR patients are the length of first remission (p = 0.01), the severity of acute GvHD (p = 0.02), and the severity of chronic GvHD (p = 0.03). This study points out an age-dependent tolerance of transplant procedures in ALL, and a high relapse rate in 2nd remission patients, possibly influenced by the duration of first remission and the severity of GvHD.

Original languageEnglish
Pages (from-to)135-138
Number of pages4
Issue number2
Publication statusPublished - 1986

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Bone marrow transplantation (BMT) for acute lymphoblastic leukemia (ALL) in remission'. Together they form a unique fingerprint.

Cite this